Nashville-Davidson, Tennessee 2020-11-20 05:23:53 –
Washington – Federal regulators have approved an emergency use of another COVID-19 treatment, the anti-inflammatory drug baricitinib, in combination with drugs already used to treat critically ill inpatients.
On Thursday, the Food and Drug Administration approved new use of Eli Lilly’s Pyrvaricitinib and Remdesivir for hospitalized adults and children over the age of 2 who require oxygen or ventilation therapy.
Remdesivir is the first and only drug approved by the FDA to treat COVID-19. Baricitinib emergency clearance acts as a preliminary approval until more data are available to show the efficacy of COVID-19.
The FDA said the drug combination appears to reduce recovery time in inpatients compared to patients receiving remdesivir alone.
Authorities said ongoing research was needed to confirm the benefits.
Based in Indianapolis, Lily already sells baricitinib as an ormianto to treat the less common rheumatoid arthritis that occurs when the immune system attacks joints and causes inflammation. An excessive immune system can also cause serious problems in coronavirus patients.
The FDA was determined based on a study of 1,000 patients who were randomly assigned to receive baricitinib and remdesivir, or a combination of remdesivir and placebo. This study was conducted by the National Institute of Health.
Eli Lilly arthritis drug gets emergency use nod as COVID-19 treatment Source link Eli Lilly arthritis drug gets emergency use nod as COVID-19 treatment